Alltrna
alltrna.com
Actively hiring
Rare Disease Therapeutics
Cell & Gene Therapy
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
News
Alltrna Announces Approval to Initiate First-in-Human Clinical Trial of AP003, the First tRNA Therapeutic to Enter Clinical Trials
/PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe...
Read more
Report
Alltrna Eyes First Clinical Trial for tRNA Drug Targeting Nonsense Mutations
The firm's first candidate, AP003, will focus on rare genetic liver diseases caused by nonsense mutations that prematurely halt protein production.
Read more
Report
Report
Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation
At JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and rare-disease drug development.
Read more
Report
C&EN's 10 Start-Ups to Watch for 2022
The central science spawns new companies solving diverse problems
Read more
Report
Alltrna Appoints David Hava, Ph.D., Chief Scientific Officer to Drive Strategic Pipeline Advancement of tRNA Medicines
Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA medicines to regulate the protein universe and resolve disease, today announced the appointment of David (Dave) Hava, Ph.D., as Chief Scientific Officer (CSO)
Read more
Report
New tRNA tech aims to rewrite rare disease treatment
Alltrna is redefining the future of rare disease treatment with engineered tRNA therapeutics that target genetic mutations - not just individual diseases. CEO Michelle Werner shares how this bold, mutation-driven approach could unlock universal treatments
Read more
Report
Alltrna plans to tackle rare diseases using tRNA-based therapies
Alltrna's CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases together.
Read more
Report
Podcast: Treating Rare Diseases With tRNA
In this episode of the In Vivo podcast Michelle Werner, CEO of Alltrna, discusses using tRNA as a therapeutic modality for rare diseases.
Read more
Report
Report
Show more news
Tech stack
Technologies named in job postings at Alltrna over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
64/100
Cloud & platforms
GCP
Sign in to see how your skills match this stack
Sign In
Salary insights
Compensation ranges based on this company's open jobs
Median
$283k
Typical range
$236k – $330k
Open positions
2
2
Jobs
Principal
50%
Architect
50%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Principal | 1 | $236k | $236k |
| Architect | 1 | $330k | $330k |
Highest paying role
VP, Program Management & Business Operations
$330k
Normalized to USD per year
Growth
Hiring Momentum
45/100
Stable
Open positions
2
0 opened / 1 closed in 30 days
Median time-to-fill
44 days
faster than 30% of the market
ATS activity
Every ~4 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
100% ▼
Offices
Where the company hires and what each office is for
Cities
4
Hiring now
1
Countries
1
Busiest office
Cambridge
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Cambridge
United States
Regional office
Generate Biomedicines
2 open roles 1 posted in 90 days 50% engineering $283k Avg Salary
hires for Operations, Science & Research
20 Acorn Park Dr, Suite 300, Cambridge, MA 02140
Boston
United States
Regional office
Integral Health
Somerville
United States
Regional office
Invaio Sciences
Health
United States
Regional office
Health Security